Schultz Kirk R, Pullen D Jeanette, Sather Harland N, Shuster Jonathan J, Devidas Meenakshi, Borowitz Michael J, Carroll Andrew J, Heerema Nyla A, Rubnitz Jeffrey E, Loh Mignon L, Raetz Elizabeth A, Winick Naomi J, Hunger Stephen P, Carroll William L, Gaynon Paul S, Camitta Bruce M
Children's Oncology Group, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, Canada.
Blood. 2007 Feb 1;109(3):926-35. doi: 10.1182/blood-2006-01-024729. Epub 2006 Sep 26.
The Children's Cancer Group (CCG) and the Pediatric Oncology Group (POG) joined to form the Children's Oncology Group (COG) in 2000. This merger allowed analysis of clinical, biologic, and early response data predictive of event-free survival (EFS) in acute lymphoblastic leukemia (ALL) to develop a new classification system and treatment algorithm. From 11 779 children (age, 1 to 21.99 years) with newly diagnosed B-precursor ALL consecutively enrolled by the CCG (December 1988 to August 1995, n=4986) and POG (January 1986 to November 1999, n=6793), we retrospectively analyzed 6238 patients (CCG, 1182; POG, 5056) with informative cytogenetic data. Four risk groups were defined as very high risk (VHR; 5-year EFS, 45% or below), lower risk (5-year EFS, at least 85%), and standard and high risk (those remaining in the respective National Cancer Institute [NCI] risk groups). VHR criteria included extreme hypodiploidy (fewer than 44 chromosomes), t(9;22) and/or BCR/ABL, and induction failure. Lower-risk patients were NCI standard risk with either t(12;21) (TEL/AML1) or simultaneous trisomies of chromosomes 4, 10, and 17. Even with treatment differences, there was high concordance between the CCG and POG analyses. The COG risk classification scheme is being used for division of B-precursor ALL into lower- (27%), standard- (32%), high- (37%), and very-high- (4%) risk groups based on age, white blood cell (WBC) count, cytogenetics, day-14 marrow response, and end induction minimal residual disease (MRD) by flow cytometry in COG trials.
儿童癌症研究组(CCG)和儿科肿瘤学组(POG)于2000年合并组建了儿童肿瘤学组(COG)。此次合并使得对急性淋巴细胞白血病(ALL)中预测无事件生存期(EFS)的临床、生物学和早期反应数据进行分析成为可能,从而开发出一种新的分类系统和治疗算法。我们从CCG(1988年12月至1995年8月,n = 4986)和POG(1986年1月至1999年11月,n = 6793)连续纳入的11779例新诊断的B系前体ALL儿童(年龄1至21.99岁)中,回顾性分析了6238例具有信息性细胞遗传学数据的患者(CCG,1182例;POG,5056例)。定义了四个风险组,即极高风险(VHR;5年EFS为45%或更低)、低风险(5年EFS至少为85%)以及标准风险和高风险(分别属于各自的美国国立癌症研究所 [NCI] 风险组)。VHR标准包括极度亚二倍体(染色体少于44条)、t(9;22)和/或BCR/ABL以及诱导失败。低风险患者为具有t(12;21)(TEL/AML1)或同时存在4号、10号和17号染色体三体的NCI标准风险患者。即便存在治疗差异,CCG和POG的分析之间仍具有高度一致性。在COG试验中,COG风险分类方案正用于根据年龄、白细胞(WBC)计数、细胞遗传学、第14天骨髓反应以及流式细胞术检测的诱导末期微小残留病(MRD),将B系前体ALL分为低风险(27%)、标准风险(32%)、高风险(37%)和极高风险(4%)组。